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Abstract
Mitochondrial dysfunction has been implicated in rare and common forms of type 2 diabetes (T2DM). Additionally, rare
mitochondrial DNA (mtDNA) mutations have been shown to be causal for T2DM pathogenesis. So far, many studies have
investigated the possibility that mtDNA variation might affect the risk of T2DM, however, when found, haplogroup
association has been rarely replicated, even in related populations, possibly due to an inadequate level of haplogroup
resolution. Effects of mtDNA variation on diabetes complications have also been proposed. However, additional studies
evaluating the mitochondrial role on both T2DM and related complications are badly needed. To test the hypothesis of a
mitochondrial genome effect on diabetes and its complications, we genotyped the mtDNAs of 466 T2DM patients and 438
controls from a regional population of central Italy (Marche). Based on the most updated mtDNA phylogeny, all 904 samples
were classified into 57 different mitochondrial sub-haplogroups, thus reaching an unprecedented level of resolution. We
then evaluated whether the susceptibility of developing T2DM or its complications differed among the identified
haplogroups, considering also the potential effects of phenotypical and clinical variables. MtDNA backgrounds, even when
based on a refined haplogroup classification, do not appear to play a role in developing T2DM despite a possible protective
effect for the common European haplogroup H1, which harbors the G3010A transition in the MTRNR2 gene. In contrast, our
data indicate that different mitochondrial haplogroups are significantly associated with an increased risk of specific diabetes
complications: H (the most frequent European haplogroup) with retinopathy, H3 with neuropathy, U3 with nephropathy,
and V with renal failure.
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Introduction
The etiology of type 2, or non-insulin-dependent, diabetes mel-
litus (T2DM), the most common metabolic disease in the Western
hemisphere, is the result of an interaction of environmental factors
with a combination of genetic variants, most of which are still
unknown. Case-control studies can be used to predict and quantify
the association of genetic factors and lifestyle with some common
diseases, thus contributing to the body of knowledge of primary
prevention for these conditions. Different genome-wide association
studies have led to recent discoveries of novel diabetes-related
nuclearloci [1–3],which often fail to be replicated and confirmed in
different populations, possibly because of population-specific sus-
ceptibility patterns [4]. This may reflect differences in the genetic
structure of human populations, each with its peculiar evolutionary
history, for instance turning minor alleles in a certain population to
prevalent ones in another population, and thus deeply affecting the
frequencies of allele combinations.
Obviously, the possibility of obtaining false positive/negative
results is greatly decreased when patients and controls come from
the same population and/or geographic area where the genetic
background should be more homogenous. This is particularly true
when association studies involve a genetic system such as the
maternally transmitted mitochondrial DNA (mtDNA), whose
PLoS ONE | www.plosone.org 1 June 2011 | Volume 6 | Issue 6 | e21029worldwide ‘‘natural’’ sequence variation is geographically and
ethnically differentiated. MtDNA haplotypes and haplogroups
(groups of mtDNA haplotypes sharing the same mutational motifs
by descent from a common female ancestor) are extremely com-
mon in one continent or even a single geographic area/population
group, but completely absent in all others [5,6].
Mitochondrial involvement in the pathogenesis of major com-
monmetabolicdisorders,includingT2DM,stemsfromtheobserva-
tion of dysfunctions in the mitochondrial energy production
machinery (OXPHOS) of many patients [7–10]. Single mtDNA
mutations, including both major rearrangements and point mu-
tations, and/or mitochondrial haplogroups have been associated
with conditions of type 2 diabetes. For instance a protective role has
been attributed to the Asian haplogroup N9a [11,12] and to the
Western Eurasian haplogroup J1 [13], while the super-haplogroup
J/T and the T haplogroup alone have been associated with an
increased risk of diabetes in Europeans [14]. Yet, most studies either
failed to report definitive associations between T2DM and variation
in the mitochondrial genome, or even conflicting results have been
observed [15–17]. Thus, all associations reported so far between
mtDNA mutations (or haplogroups) and diabetes, with the excep-
tion of the rare mutations associated with Maternally Inherited
Diabetes and Deafness (MIDD, [MIM #520000]), remain pro-
visional (see Mitomap for a review http://www.mitomap.org/
MITOMAP).This isnot a featurerestrictedtoT2DM.Indeed, with
the exception of Leber Hereditary Optic Neuropathy (LHON), the
association between disorders and mtDNA haplogroups has rarely
been replicated by studies in other populations [18,19]. Association
studies can be confounded if patients and controls are poorly
characterized or not well matched. However, mtDNA association
studies are probably affected also by another major specific
problem: the level of resolution employed in the classification of
mtDNA haplogroups has been generally very low. Recent studies
confirm that mtDNA association analyses performed so far have
often been too simplistic. A striking example is represented by
haplogroup H, by far the most common haplogroup in Europe with
a uniformly high frequency (30%–50%), which is formed by many
sub-haplogroups whose frequencies vary considerably across Eu-
rope [20,21]. Such a degree of difference in frequency distribution
of mtDNA sub-haplogroups alone could easily explain some of the
inconsistent results obtained by association studies carried out in
different European populations.
A second general area of investigation concerns the role of
mtDNA variants or haplogroups in modulating susceptibility to
develop diabetes complications, usually classified into macrovas-
cular (cardiovascular disease, cerebrovascular accidents, and peri-
pheral vascular disease) and microvascular complications (diabetic
nephropathy, neuropathy, and retinopathy) [22,23], but the num-
ber of mtDNA studies that, in addition to the "whole" T2DM
phenotype, have also evaluated diabetes complications is still
limited [24–26].
In this study, to evaluate the role of mtDNA backgrounds, not
only in T2DM as a whole but also in its associated complications,
we have genotyped, at an extremely high level of phylogenetic
resolution, the mitochondrial genome of a large number of
subjects (466 T2DM patients and 438 controls) from the Marche
region of central Italy.
Results
Before determining the extent and nature of mtDNA variation
in control and diabetic subjects from the Marche region, we
investigated the effects of a large number of phenotypical and
clinical variables on the risk of T2DM. Some of the traits
evaluated in the 904 subjects are shown in Table 1. No difference
in the risk of T2DM was found only for fibrinogen and C-reactive
protein. As expected, among the strongest predictors of diabetes
were age, BMI (and consequently obesity), metabolic syndrome,
insulin resistance evaluated by homeostasis model assessment
(HOMA), glycated hemoglobin (HbA1c), high-density lipoprotein
(HDL) cholesterol, triglycerides, and hypertension. All these
parameters, except HDL cholesterol, were much higher in patients
than in controls. However, there was also one unexpected finding,
also in light of the randomly selected gender of participants: a
significantly increased risk for males and smokers was noted
(p-values of ,0.0001 and 0.001, respectively). Assuming that BMI
might be considered as a general indicator of health, we found
that the BMI is just slightly lower among smokers (27.364.2 vs
28.264.7).
T2DM and mtDNA haplogroups
All 904 mtDNAs were genotyped and assigned to 57 different
mtDNA haplogroups and sub-haplogroups (Table S1). This
classification was based on the most updated phylogeny [27],
thus reaching an unprecedented level of resolution. As summa-
rized in Table 2, more than 97% of the mtDNAs belonged to
typical Western Eurasian lineages, i.e. H*, H1, H3, H5, H6, H8,
H9, HV*, HV0, V, R0a, J1, J2, T1, T2, U1, U2, U3, U4, U5, U6,
U7, U8, U9, K1, K2, N1, I, W, X2. The only notable exceptions
were represented by 24 mtDNAs: 8 attributed to the Eastern Asian
clade D4 and 16 classified into three typical African haplogroups
(M1, L1b and L3).
When we compared haplogroup distributions of T2DM cases
and controls (Table 2), multiple logistic-regression analysis showed
that subjects harboring haplogroup H1 (9.4% and 15.8% in
patients and controls, respectively) might be characterized by a
reduced risk of T2DM (OR=0.5576, 95% CI: 0.3726–0.8344, p-
value=0.0045), and that H1 was indeed the only haplogroup
included in the final step-wise model (p-value=0.004). However,
such a p-value does not reach the statistical significance established
at a#0.003, after the Bonferroni correction. We then examined
whether the possible protective effect of haplogroup H1 towards
T2DM was related to age, gender, obesity, smoking, and/or to
some clinical traits such as BMI, metabolic syndrome, insulin
resistance, fibrinogen, C-reactive protein, HbA1c, HDL, triglyc-
erides and hypertension. None of the parameters showed sig-
nificant differences between the subjects with haplogroup H1 and
those without it (data not shown).
Table 2 illustrates a second interesting finding. Haplogroup
R0a, which was not included in the logistic-regression analysis
because of its low frequency (0.7%), was detected only in diabetic
patients (six out of six R0a mtDNAs), thus raising the possibility of
a potential effect by this rare haplogroup. The presence of three
different R0a control-region haplotypes among the six subjects
(Table S1) excludes the possibility of a founder event. Two possible
scenarios can be envisioned to explain the detection of this
haplogroup only in diabetic patients: (i) R0a might actually
increase the risk of T2DM, consequently decreasing its detection
rate in healthy subjects older than 40 years; (ii) the mtDNA
background which may be modulating the appearance of diabetes
is not the entire haplogroup R0a, but only one of its internal
branches. To discriminate between the two alternative scenarios,
we completely sequenced and included all six R0a mtDNAs in
an updated R0a phylogeny (Figure 1). Data from the complete
sequencing show that all six genomes from Marchigian diabetic
patients belong to the same sub-clade named R0a2. This clade
differs from the root of haplogroup R0a by three mutations. A T
insertion in the control region at nucleotide position (np) 60 and
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PLoS ONE | www.plosone.org 3 June 2011 | Volume 6 | Issue 6 | e21029Table 2. Frequencies of the major mitochondrial DNA haplogroups and sub-haplogroups in diabetic patients and controls.
All samples Males Females
Haplogroup
a Patients (%) Controls (%) Patients (%) Controls (%) Patients (%) Controls (%) Total (%)
N=466 N=438 N=257 N=176 N=209 N=262 N=904
H: 161 (34.55%) 181 (41.34%) 90 (35.01%) 66 (37.50%) 71 (33.96%) 115 (43.89%) 342 (37.83%)
H* 77 (16.52%) 72 (16.44%) 43 (16.73%) 29 (16.48%) 34 (16.27%) 43 (16.41%) 149 (16.48%)
H1 44 (9.44%) 69 (15.75%) 23 (8.95%) 23 (13.07%) 21 (10.05%) 46 (17.56%) 113 (12.50%)
H3 10 (2.15%) 13 (2.97%) 6 (2.33%) 8 (4.55%) 4 (1.91%) 5 (1.91%) 23 (2.54%)
H5 16 (3.43%) 17 (3.88%) 11 (4.28%) 3 (1.70%) 5 (2.39%) 14 (5.34%) 33 (3.65%)
H6 10 (2.15%) 7 (1.60%) 5 (1.95%) 2 (1.14%) 5 (2.39%) 5 (1.91%) 17 (1.88%)
H8 … 2 (0.46%) … 1 (0.57%) … 1 (0.38%) 2 (0.22%)
H9 4 (0.86%) 1 (0.23%) 2 (0.78%) … 2 (0.96%) 1 (0.38%) 5 (0.55%)
HV
b: 37 (7.94%) 29 (6.62%) 25 (9.73%) 13 (7.39%) 12 (5.74%) 16 (6.11%) 66 (7.30%)
HV* 15 (3.22%) 17 (3.88%) 8 (3.11%) 9 (5.11%) 7 (3.35%) 8 (3.05%) 32 (3.54%)
HV0 4 (0.86%) 1 (0.23%) 3 (1.17%) … 1 (0.48%) 1 (0.38%) 5 (0.55%)
V 18 (3.86%) 11 (2.51%) 14 (5.45%) 4 (2.27%) 4 (1.91%) 7 (2.67%) 29 (3.21%)
R0: 6 (1.29%) … 3 (1.17%) … 3 (1.44%) … 6 (0.66%)
R0a 6 (1.29%) … 3 (1.17%) … 3 (1.44%) … 6 (0.66%)
J: 33 (7.08%) 37 (8.45%) 21 (8.17%) 19 (10.80%) 12 (5.74%) 18 (6.87%) 70 (7.75%)
J1 27 (5.79%) 31 (7.08%) 18 (7.00%) 16 (9.09%) 9 (4.31%) 15 (5.73%) 58 (6.42%)
J2 6 (1.29%) 6 (1.37%) 3 (1.17%) 3 (1.70%) 3 (1.44%) 3 (1.15%) 12 (1.33%)
T: 71 (15.24%) 57 (13.01%) 37 (14.39%) 23 (13.07%) 34 (16.27%) 34 (12.98%) 128 (14.16%)
T1 12 (2.58%) 11 (2.51%) 7 (2.72%) 3 (1.70%) 5 (2.39%) 8 (3.05%) 23 (2.54%)
T2 59 (12.66%) 46 (10.50%) 30 (11.67%) 20 (11.36%) 29 (13.88%) 26 (9.92%) 105 (11.62%)
UK:
U 80 (17.17%) 65 (14.84%) 48 (18.68%) 25 (14.20%) 32 (15.31%) 40 (15.26%) 145 (16.04%)
U1 3 (0.64%) 4 (0.91%) 3 (1.17%) 2 (1.14%) … 2 (0.76%) 7 (0.77%)
U2 1 (0.21%) 1 (0.23%) 1 (0.39%) … … 1 (0.38%) 2 (0.22%)
U3 13 (2.79%) 11 (2.51%) 10 (3.89%) 4 (2.27%) 3 (1.44%) 7 (2.67%) 24 (2.65%)
U4 12 (2.58%) 8 (1.83%) 6 (2.33%) 5 (2.84%) 6 (2.87%) 3 (1.15%) 20 (2.21%)
U5 39 (8.37%) 34 (7.76%) 21 (8.17%) 10 (5.68%) 18 (8.61%) 24 (9.16%) 73 (8.08%)
U6 2 (0.43%) 1 (0.23%) … 1 (0.57%) 2 (0.96%) … 3 (0.33%)
U7 4 (0.86%) 2 (0.46%) 2 (0.78%) 1 (0.57%) 2 (0.96%) 1 (0.38%) 6 (0.66%)
U8 5 (1.07%) 4 (0.91%) 4 (1.56%) 2 (1.14%) 1 (0.48%) 2 (0.76%) 9 (1.00%)
U9 1 (0.21%) … 1 (0.39%) … … … 1 (0.11%)
K 31 (6.65%) 24 (5.48%) 12 (4.67%) 15 (8.52%) 19 (9.09%) 9 (3.44%) 55 (6.08%)
K1 30 (6.44%) 22 (5.02%) 12 (4.67%) 13 (7.39%) 18 (8.61%) 9 (3.44%) 52 (5.75%)
K2 1 (0.21%) 2 (0.46%) … 2 (1.14%) 1 (0.48%) … 3 (0.33%)
N1: 17 (3.65%) 9 (2.05%) 9 (3.50%) 1 (0.57%) 8 (3.83%) 8 (3.05%) 26 (2.88%)
N1 9 (1.93%) 6 (1.37%) 6 (2.33%) 1 (0.57%) 3 (1.44%) 5 (1.91%) 15 (1.66%)
I 8 (1.72%) 3 (0.68%) 3 (1.17%) … 5 (2.39%) 3 (1.15%) 11 (1.22%)
N2: 6 (1.29%) 8 (1.83%) 3 (1.17%) 4 (2.27%) 3 (1.44%) 4 (1.53%) 14 (1.55%)
W 6 (1.29%) 8 (1.83%) 3 (1.17%) 4 (2.27%) 3 (1.44%) 4 (1.53%) 14 (1.55%)
X: 13 (2.79%) 15 (3.42%) 4 (1.56%) 5 (2.84%) 9 (4.31%) 10 (3.82%) 28 (3.10%)
X2 13 (2.79%) 15 (3.42%) 4 (1.56%) 5 (2.84%) 9 (4.31%) 10 (3.82%) 28 (3.10%)
M: 10 (2.15%) 8 (1.82%) 5 (1.95%) 3 (1.70%) 5 (2.39%) 5 (1.91%) 18 (1.99%)
D4 5 (1.07%) 3 (0.68%) 4 (1.56%) 2 (1.14%) 1 (0.48%) 1 (0.38%) 8 (0.88%)
M1 5 (1.07%) 5 (1.14%) 1 (0.39%) 1 (0.57%) 4 (1.91%) 4 (1.53%) 10 (1.11%)
L: 1 (0.21%) 5 (1.14%) … 2 (1.14%) 1 (0.48%) 3 (1.15%) 6 (0.66%)
L1b … 1 (0.23%) … … … 1 (0.38%) 1 (0.11%)
L3 1 (0.21%) 4 (0.91%) … 2 (1.14%) 1 (0.48%) 2 (0.76%) 5 (0.55%)
Role of mtDNA in Type 2 Diabetes and Complications
PLoS ONE | www.plosone.org 4 June 2011 | Volume 6 | Issue 6 | e21029the non-synonymous transition MTCYB-T15674C/S310P are
shared with the sister branch R0a3, whereas the third mutation,
the transition A2355G in the 16S rRNA gene, is distinctive of
R0a2 (Figure 1).
T2DM complications and mitochondrial haplogroups
Many studies have evaluated mtDNA variation in T2DM pa-
tients. However, only a few studies have tested mtDNA
haplogroups for association with diabetes complications. In an
attempt to investigate a potential role of mtDNA backgrounds in
complications rather than in T2DM as a whole, we evaluated this
issue in our population sample. Table 3 reports the haplogroup
distributions observed in patients with only the diabetic phenotype
and no complications and in T2DM patients characterized by the
development of at least one (or at least two) of six common T2DM
complications. These complications include the following: reti-
nopathy, somatic neuropathy, nephropathy, renal failure, cardiac
ischemia, and peripheral artery occlusive disease (see Tables S2,
S3, S4, S5, S6, and S7 for details concerning each complication).
Even if T2DM complications were determined by different
molecular mechanisms, the concomitant analysis of grouped
complications provides some initial clues concerning the role of
mitochondrial haplogroups in modulating the pathology course.
Then, this is further investigated by analyzing each candidate
haplogroup in relation to patients’ traits and complications.
Evidence of association was observed only for haplogroup H3
that seemed to increase the probability of developing at least one
complication by almost 8.5 fold (Table 4). In particular, when we
aH* is a paragroup that encompasses all H mtDNAs that did not belong to any of the tested subclades of H.
bWithout H.
doi:10.1371/journal.pone.0021029.t002
Table 2. Cont.
Figure 1. Schematic phylogeny of haplogroup R0a encompassing seven complete mtDNA sequences from diabetic patients. The
schematic classification of the R0a sub-clades is based on C ˇerny ´ et al. [42], while the R0a’b node is newly defined on the basis of the complete
genome #7. Sequences #1–7 were obtained in the course of this study and are from Italian diabetic patients: sequences #1–6 (GenBank accession
numbers JF717355-JF717360) are from subjects of the Marche region sample, while sequence #7 (GenBank accession number JF717361) is from a
diabetic patient not included in the current study because the maternal ancestry was from a different region (Campania, Southern Italy). Three
control mtDNA sequences from the literature (GenBank accession numbers HM185239, HM185241 [42] and AY738940 [20]), which clustered in the
same sub-branches of the sequences obtained from the diabetic subjects, were also included in the tree. The position of the revised Cambridge
Reference Sequence (rCRS) [43] – a member of haplogroup H2a2 – is indicated for reading off sequence motifs. Mutations are shown on the
branches; they are transitions unless a base is explicitly indicated. The prefix @ designates reversions, while suffixes indicate transversions (toA ,G ,C ,
or T), insertions (+), gene locus (,t, tRNA; ,r, rRNA; nc, non coding region outside of the control region) and synonymous or non synonymous
changes (s or ns). Recurrent mutations within the phylogeny are underlined.
doi:10.1371/journal.pone.0021029.g001
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PLoS ONE | www.plosone.org 5 June 2011 | Volume 6 | Issue 6 | e21029Table 3. Frequencies of mtDNA haplogroups and sub-haplogroups in patients with only the diabetic phenotype and diabetic
patients also affected by at least one or two of six common complications [retinopathy, somatic neuropathy, cardiac ischemia,
nephropathy, peripheral artery occlusive disease (PAOD), and/or renal failure].
All Samples
a Males Females
No
complications
At least one
complication
At least two
complications
No
complications
At least one
complication
At least two
complications
No
complications
At least one
complication
At least two
complications
N=223 N=243 N=109 N=111 N=146 N=69 N=112 N=97 N=40
H: 68 (30.49%) 93 (38.27%) 49 (44.95%) 34 (30.64%) 56 (38.38%) 29 (42.03%) 34 (30.36%) 37 (38.16%) 20 (50.00%)
H* 34 (15.25%) 43 (17.70%) 26 (23.85%) 18 (16.22%) 25 (17.12%) 14 (20.29%) 16 (14.29%) 18 (18.56%) 12 (30.00%)
H1 19 (8.52%) 25 (10.29%) 12 (11.01%) 9 (8.11%) 14 (9.59%) 8 (11.59%) 10 (8.93%) 11 (11.34%) 4 (10.00%)
H3 1 (0.45%) 9 (3.70%) 6 (5.50%) ??? 6 (4.11%) 3 (4.35%) 1 (0.89%) 3 (3.09%) 3 (7.50%)
H5 8 (3.59%) 8 (3.29%) 3 (2.75%) 6 (5.41%) 5 (3.42%) 3 (4.35%) 2 (1.79%) 3 (3.09%) ???
H6 4 (1.79%) 6 (2.47%) 2 (1.83%) 1 (0.90%) 4 (2.74%) 1 (1.45%) 3 (2.68%) 2 (2.06%) 1 (2.50%)
H9 2 (0.90%) 2 (0.82%) ??? ??? 2 (1.37%) ??? 2 (1.79%) ??? ???
HV: 20 (8.97%) 17 (7.00%) 8 (7.34%) 11 (9.91%) 14 (9.59%) 8 (11.59%) 9 (8.04%) 3 (3.09%) ???
HV* 10 (4.48%) 5 (2.06%) ??? 5 (4.50%) 3 (2.05%) ??? 5 (4.46%) 2 (2.06%) ???
HV0 2 (0.90%) 2 (0.82%) 1 (0.92%) 2 (1.80%) 1 (0.68%) 1 (1.45%) ??? 1 (1.03%) ???
V 8 (3.59%) 10 (4.12%) 7 (6.42%) 4 (3.60%) 10 (6.85%) 7 (10.14%) 4 (3.57%) ??? ???
R0: 2 (0.90%) 4 (1.65%) 1 (0.92%) ??? 3 (2.05%) 1 (1.45%) 2 (1.79%) 1 (1.03%) ???
R0a 2 (0.90%) 4 (1.65%) 1 (0.92%) ??? 3 (2.05%) 1 (1.45%) 2 (1.79%) 1 (1.03%) ???
J: 17 (7.62%) 16 (6.58%) 5 (4.59%) 10 (9.01%) 11 (7.53%) 4 (5.80%) 7 (6.25%) 5 (5.15%) 1 (2.50%)
J1 13 (5.83%) 14 (5.76%) 5 (4.59%) 7 (6.31%) 11 (7.53%) 4 (5.80%) 6 (5.36%) 3 (3.09%) 1 (2.50%)
J2 4 (1.79%) 2 (0.82%) ??? 3 (2.70%) ??? ??? 1 (0.89%) 2 (2.06%) ???
T: 41 (18.39%) 30 (12.35%) 13 (11.93%) 22 (19.82%) 15 (10.27%) 7 (10.14%) 19 (16.96%) 15 (15.46%) 6 (15.00%)
T1 6 (2.69%) 6 (2.47%) 3 (2.75%) 2 (1.80%) 5 (3.42%) 2 (2.90%) 4 (3.57%) 1 (1.03%) 1 (2.50%)
T2 35 (15.70%) 24 (9.88%) 10 (9.17%) 20 (18.02%) 10 (6.85%) 5 (7.25%) 15 (13.39%) 14 (14.43%) 5 (12.50%)
UK:
U 36 (16.14%) 44 (18.10%) 19 (17.43%) 18 (16.22%) 30 (20.55%) 12 (17.39%) 18 (16.06%) 14 (14.43%) 7 (17.50%)
U1 1 (0.45%) 2 (0.82%) 1 (0.92%) 1 (0.90%) 2 (1.37%) 1 (1.45%) ??? ??? ???
U2 ??? 1 (0.41%) ??? ??? 1 (0.68%) ??? ??? ??? ???
U3 6 (2.69%) 7 (2.88%) 6 (5.50%) 5 (4.50%) 5 (3.42%) 4 (5.80%) 1 (0.89%) 2 (2.06%) 2 (5.00%)
U4 7 (3.14%) 5 (2.06%) 1 (0.92%) 2 (1.80%) 4 (2.74%) ??? 5 (4.46%) 1 (1.03%) 1 (2.50%)
U5 19 (8.52%) 20 (8.23%) 8 (7.34%) 8 (7.21%) 13 (8.90%) 5 (7.25%) 11 (9.82%) 7 (7.22%) 3 (7.50%)
U6 ??? 2 (0.82%) ??? ??? ??? ??? ??? 2 (2.06%) ???
U7 2 (0.90%) 2 (0.82%) ??? 1 (0.90%) 1 (0.68%) ??? 1 (0.89%) 1 (1.03%) ???
U8 1 (0.45%) 4 (1.65%) 2 (1.83%) 1 (0.90%) 3 (2.05%) 1 (1.45%) ??? 1 (1.03%) 1 (2.50%)
U9 ??? 1 (0.41%) 1 (0.92%) ??? 1 (0.68%) 1 (1.45%) ??? ??? ???
K 12 (5.38%) 19 (7.82%) 4 (3.67%) 2 (1.80%) 10 (6.85%) 4 (5.80%) 10 (8.93%) 9 (9.28%) ???
K1 12 (5.38%) 18 (7.41%) 4 (3.67%) 2 (1.80%) 10 (6.85%) 4 (5.80%) 10 (8.93%) 8 (8.25%) ???
K2 1 (0.41%) ??? ??? ??? ??? ??? 1 (1.03%) ???
N1: 7 (3.14%) 10 (4.12%) 5 (4.59%) 5 (4.50%) 4 (2.74%) 1 (1.45%) 2 (1.79%) 6 (6.19%) 4 (10.00%)
I 4 (1.79%) 5 (2.06%) 2 (1.83%) 4 (3.60%) 2 (1.37%) ??? ??? 3 (3.09%) 2 (5.00%)
N1 3 (1.35%) 5 (2.06%) 3 (2.75%) 1 (0.90%) 2 (1.37%) 1 (1.45%) 2 (1.79%) 3 (3.09%) 2 (5.00%)
N2: 4 (1.79%) 2 (0.82%) 1 (0.92%) 2 (1.80%) 1 (0.68%) 1 (1.45%) 2 (1.79%) 1 (1.03%) ???
W 4 (1.79%) 2 (0.82%) 1 (0.92%) 2 (1.80%) 1 (0.68%) 1 (1.45%) 2 (1.79%) 1 (1.03%) ???
X: 8 (3.59%) 5 (2.06%) 2 (1.83%) 3 (2.70%) 1 (0.68%) 1 (1.45%) 5 (4.46%) 4 (4.12%) 1 (2.50%)
X2 8 (3.59%) 5 (2.06%) 2 (1.83%) 3 (2.70%) 1 (0.68%) 1 (1.45%) 5 (4.46%) 4 (4.12%) 1 (2.50%)
M: 7 (3.14%) 3 (1.23%) 2 (1.83%) 4 (3.60%) 1 (0.68%) 1 (1.45%) 3 (2.68%) 2 (2.06%) 1 (2.50%)
D4 4 (1.79%) 1 (0.41%) 1 (0.92%) 3 (2.70%) 1 (0.68%) 1 (1.45%) 1 (0.89%) … ???
M1 3 (1.35%) 2 (0.82%) 1 (0.92%) 1 (0.90%) ??? ??? 2 (1.79%) 2 (2.06%) 1 (2.50%)
L: 1 (0.45%) ??? ??? ??? ??? ??? 1 (0.89%) ??? ???
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H3 (p-value=0.0007) (Table 5). The significance of the association
with H3 was confirmed in the logistic regression with two or more
complications, but also other groupings – the paragroup H* and
the haplogroups U3 and V – turned out to be risk factors (Table 4).
Considering the combined effect of H* and H3, it is conceivable
that the entire haplogroup H (and its basal mutational motif) might
play an important role in the development of T2DM-related
complications. This scenario is supported by the finding that the
incidence of retinopathy (Table S2) was significantly increased (p-
value=0.0007) in subjects harboring H mtDNAs (OR=2.0075,
95% CI: 1.3080-3.0812, p-value 0.0014), who also showed a slight
decrease in HDL cholesterol (50.73612.22 mg/dL vs. 53.826
15.98 mg/dL, t-test p-value=0.0202).
Finally, U3 and V subjects showed an increased occurrence of
nephropathy (OR=4.1518, 95% CI: 1.3118–13.1401, p-value
0.0154) and renal failure (OR=5.8429, 95% CI: 1.5159–22.5206,
p-value 0.0103), respectively (Table 5).
In order to compute confidence bounds around the predictions,
we tested the significant haplogroups trough a decision tree
analysis. Actually, all the reported associations were supported
(Figure S1): H3 entered in the final decision tree when analyzing
one T2DM complication, more than one complication and neu-
ropathy (p-values 0.027, 0.034 and ,0.001, respectively); while H,
U3 and V were significant predictors for retinopathy (p-value
0.036), nephropathy (p-value 0.011) and renal failure (p-value 0.019),
respectively.
Discussion
As a first step in this study, we examined the relationships
between T2DM and a wide range of mtDNA haplogroups and
sub-haplogroups in a large-scale association study carried out on
an Italian regional population. A reduced susceptibility to diabetes
was possibly detected only for the H1 mtDNA background (9.4%
and 15.8% in patients and controls, respectively). This H sub-
branch is common in Western Europe (,22% in the Iberian
Peninsula, ,13.7% in France and ,15.3% in Scandinavia) and
North Africa (average frequency of ,16%) [28], and probably
marks the expansions from the Franco-Cantabrian refuge zone
when climatic conditions improved after the Last Glacial Maxi-
mum [29]. As shown in the schematic tree of figure 2, which
illustrates the basal mutational motifs of all haplogroups associated
with T2DM and/or its complications until now, H1 differs from
the root of H only for the G3010A transition in the MTRNR2
gene. It is important to note that the same nucleotide change, due
to an independent mutational event, characterizes also haplogroup
J1 (Figure 2), whose protective role in diabetes has been previously
postulated [13]. It is also worth mentioning that polymorphic
variations in the mtDNA rRNA genes have been proposed as
All Samples
a Males Females
No
complications
At least one
complication
At least two
complications
No
complications
At least one
complication
At least two
complications
No
complications
At least one
complication
At least two
complications
N=223 N=243 N=109 N=111 N=146 N=69 N=112 N=97 N=40
L1b ??? ??? ??? ??? ??? ??? ??? ??? ???
L3 1 (0.45%) ??? ??? ??? ??? ??? 1 (0.89%) ??? ???
aHaplogroup frequencies in males and females are reported for congruency with previous tables. However, gender was not considered in statistical analyses dealing
with complications.
doi:10.1371/journal.pone.0021029.t003
Table 3. Cont.
Table 5. ‘‘Inverted’’ logistic-regression analyses employed to
evaluate characteristics associated with candidate haplogroups.
Modeled Outcome
a Characteristics p-value O.R. 95% C.I.
H3 subjects
(Sig.
b =0.0007)
1
Neuropathy 0.0012 9.6389 2.4411–38.0594
H
c subjects
(Sig.= 0.0007)
1
Retinopathy 0.0014 2.0075 1.3080–3.0812
HDL 0.0259 0.9836 0.9694–0.9980
U3 subjects
(Sig.= 0.0247)
Nephropathy 0.0154 4.1518 1.3118–13.1401
V subjects
(Sig.= 0.0276)
Renal Failure 0.0103 5.8429 1.5159–22.5206
aThe candidate haplogroup was analyzed in relation to the patients’ traits and
complications reported in Table 1.
bSignificance (p-value) relative to the final model considering all slopes = zero
(no effect of the included I.V., taken together, on the outcome), obtained by
the likelihood ratio test. The symbol 1 highlights significant values (a#0.003).
cH here represents the entire clade, thus including H*, H1, H3, H5, H6 and H9.
doi:10.1371/journal.pone.0021029.t005
Table 4. Logistic-regression analyses of haplogroups
associated with T2DM complications.
Modeled Outcome Haplogroup p-value O.R.
b 95% C.I.
c
One complication
(Sig.
a =0.0090)
H3 0.0427 8.5385 1.0730–67.9460
Two complications
(Sig.= 0.0007)
1
H* 0.0083 2.0682 1.2055–3.5481
H3 0.0044 6.5625 1.7993–23.9349
U3 0.0211 3.7500 1.2190–11.5361
V 0.0418 2.7841 1.0389–7.4610
aSignificance (p-value) relative to the final model considering all slopes = zero
(no effect of the included I.V., taken together, on the outcome), obtained by
the likelihood ratio test. The symbol 1 highlights significant values (a#0.003).
bOdd ratio.
cConfidence interval.
doi:10.1371/journal.pone.0021029.t004
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mutations causing non-syndromic deafness and LHON [30,31].
Taking into account that the entire haplogroup H is characterized
by another base substitution in MTRNR2 (G2706A), it is con-
ceivable that such a combination of polymorphisms in the same
gene might modulate susceptibility to diabetes.
Similar to haplogroup H1, the rare R0a2 branch (Figure 2),
which was found only among diabetic patients in our sample
(Table 2 and Figure 1), is also characterized by a mutation
(A2355G) in the MTRNR2 gene (Figures 2). This subclade of the
rare R0a haplogroup – 0.9% in Italy [32] – harbors also the non-
synonymous transition MTCYB-T15674C/S310P affecting an
amino acid position with a very high conservation index
(C.I.=92.31, calculated using the mtPhyl program http://eltsov.
org/mtphyl.aspx). Thus, such a molecular change might affect the
biochemical efficiency of the respiratory chain complex III.
Moreover, it should be also considered that all R02a mtDNAs
harbor a T insertion at np 60 in the H-strand replication origin, a
sequence stretch whose variation has been recently associated to
an increase of mtDNA content in T2DM patients [33].
Unfortunately, neither the association with haplogroup H1 nor
that with haplogroup R0a was statistically supported. In fact, the
R0a mtDNAs were too few to be included in the logistic regres-
sion, and H1 did not reach the established level of significance
after the Bonferroni correction (p-value.0.003). Thus, European
mtDNA haplogroups, even when analyzed at a very high level of
molecular and phylogenetic resolution, do not appear to play a
major role in T2DM as a whole, at least in the context of a well
defined population of central Italy, as that of the Marche region.
In contrast, when we evaluated the potential role of mtDNA
backgrounds in complications rather than in T2DM as a whole,
we were able to build a very significant logistic model (p-value
,0.001). We observed that four mtDNA haplogroups (H, H3, U3
and V) were associated with an increased risk of complications, in
particular with the risk of developing at least two common T2DM
complications (Table 4). Intriguingly, we found that each hap-
logroup was related to a different pathology: U3 to nephropathy,
V to renal failure, H to retinopathy, and H3 to neuropathy
(Table 5).
The excess of U3 mtDNAs among nephropathic subjects (7.8%
vs. 2.0% in T2DM controls, Table S5) is difficult to explain since
this branch is characterized only by control-region mutations and
synonymous coding-region transitions (Figure 2). A plausible ex-
planation might dwell in the incidence of its subclade U3a that is
almost 4-fold more represented in nephropathic cases (4.7% vs.
1.2%). The U3a mtDNAs share at least two non-synonymous
mutations in two different subunits of the NADH dehydrogenase
complex (MTND4L-A10506G/T13A, C.I.=46.15; MTND5-
T13934C/T533M, C.I.=15.38).
As for haplogroup V, it was found to be associated with renal
failure (15.0% in cases vs. 3.4% in T2DM controls, Table S7),
which is a pejorative condition of nephropathy. Actually, the
nephrological problems of the three identified V patients (Table
S5) always ended with renal failure (Table S7). Their mtDNAs
harbor the transition C15904T in the tRNA threonine gene that
might accentuate the possible effect of the amino-acid change
isoleucine to threonine (MTCYB-C14766T/I7L, C.I.=48.72)
distinctive of the entire superhaplogroup HV. The latter mutation,
together with the MTRNR2-G2706A transition, could be also
involved in the 2-fold increased risk of retinopathy for diabetic
patients (44.7% in patients vs. 30.5% in T2DM controls, Table S2)
belonging to H, the most common European haplogroup (Table 5).
Within haplogroup H, it is difficult to provide an explanation
for the pejorative role of H3 with regard to neuropathy. Indeed
Figure 2. MtDNA tree encompassing the roots of haplogroups associated with T2DM and/or its complications. The distinguishing
mutational motifs for the haplogroups shown in the tree are reported on the branches and they are transitions unless a base is explicitly indicated. The
position of the rCRS [43] is indicated for reading off sequence motifs. Suffixes indicate transversions (to A), insertions (+), synonymous or non-synonymous
changes(s or ns), gene locus(for tRNA, rRNA and non-synonymous mutations – following the nomenclature proposedbyMITOMAP). A role for haplogroups
R0a/R0a2,H,H1,H3/H3 h,V,andU3/U3ahasbeenproposedinthisstudy.Theprotectiveorpejorativehaplogroupeffectisindicatedbydownoruparrows.
Continuous arrow lines mean highly significant values. Previous analyses found associations (gray arrows) with J1 [13], JT and T [14], and N9a [11,12].
doi:10.1371/journal.pone.0021029.g002
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MTCOI-T6776C (Figure 2). However, through a complete se-
quence analysis of H3 mtDNAs (data not shown), we were able to
identify a new internal branch of H3 (named H3h in Figure 2) de-
fined by the amino acid change MTND5-T12811C/Y53H (C.I.=
53.85). The incidence of this subgroup within H3 is much higher
among the neuropathic patients (57%) than in controls (37%).
Overall, we observed that most of the candidate branches in the
mtDNA tree are characterized by mutations in the MTRNR2
gene and amino acid changes affecting cytochrome b and subunits
of the respiratory enzyme complex I (Figure 2). Actually, recent
evidence of a stable mitochondrial supercomplex (I–III) [34–36]
raises the possibility that amino acid changes in the two complexes
might directly interact with each other, eventually increasing ROS
production and in this way influencing the onset of diabetic
complications involving neuronal tissues (neuropathy and retinop-
athy) [37] and nephronal structures (nephropathy and renal fail-
ure) [38], tissues that are highly susceptible to oxidative damage.
In conclusion, our data appear to indicate that mitochondrial
backgrounds do not play a significant role in causing the onset
of type 2 diabetes, despite indications of a protective effect for
haplogroup H1 – possibly due to the G3010A transition in the
MTRNR2 gene. As H1 is common in Western Europe, such a
possibility might be further evaluated by assaying diabetic cohorts
(and matched controls) of other European populations (see below).
In contrast, we found significant associations between some
European mtDNA haplogroups and typical diabetes compli-
cations. We cannot exclude that these associations might be influ-
enced by nuclear genomic backgrounds and genetic substructure
of the analyzed population, or biased by the reduced statistical
power due to the decreased sample size of subgroups (patients with
T2DM complications ascribed to different haplogroups) [39].
When we evaluated the latter scenario by calculating the power
values for each haplogroup (Table 6) according to a previously
described method [40], we observed, as would be expected due to
the high haplogroup resolution of this study, rather low power
values ranging from 4.4% to 42.8%. Taking into account the size
of our samples (about 450 cases and 450 controls), even for
haplogroup H - the most common in our study - we would be able
to reach a 90% power value only if there was a frequency dif-
ference $40% in the T2DM group relative to the control group
(41%). On the other hand, the finding that the highest power
values were generally observed for the same haplogroups for which
we found an association with T2DM (H1 and possibly R0a) and
T2DM complications (H, H3, U3 and V) tends to support the
scenario that these haplogroups do indeed play a role in T2DM
complications. It should also be pointed out that our power
analysis results raise the possibility that additional associations
between mtDNA haplogroups and diabetes complications might
exist and that they were not detected in our study simply because
the analyzed cohorts were not large enough to have the power to
identify small effects.
In brief, our study provides important clues indicating that
certain mtDNA haplogroups might modulate diabetes complica-
tions. Obviously to definitively link mtDNA backgrounds with
T2DM complications additional studies at the same level of
phylogenetic resolution in other populations with similar hap-
logroup/subhaplogroup profiles are required. It is also likely that
Table 6. Power values calculated for each haplogroup in different comparisons.
Haplogroup
a Power (%)
b
T2DM Patients/Controls
At least one complication/
No complications
At least two complications/
One or no complications
H1 42.81 6.12 5.28
H3 6.60 31.46 18.30
H5 4.99 4.49 4.79
H6 6.07 5.43 4.53
H
c 4.42 5.07 14.59
HV
d 4.37 11.98 17.81
V 10.15 4.67 9.51
R0a 31.50 n.d. n.d.
J 6.78 5.06 8.08
T1 4.40 4.44 4.44
T2 8.62 19.82 8.60
U3 4.67 20.66 11.77
U5 4.79 4.42 4.91
U4/U9 8.37 4.97 5.82
U8b/K 6.65 13.91 7.08
N1 12.86 5.69 5.13
X2 5.42 8.18 5.82
aThese haplogroups (excluding R0a) correspond to those tested in the logistic regression models.
bPower percentages were calculated as reported in [40]. The number of cases (Nc) was assumed different in each comparison, while the number of haplogroups (NH)
was always set at 16. The underlined power values refer to haplogroups H1, R0a and the other haplogroups that were statistically significant in the logistic models (see
Table 4).
cH here includes H*, H8 and H9 of Tables 2 and 3.
dHV here includes HV* and HV0 of Tables 2 and 3.
doi:10.1371/journal.pone.0021029.t006
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passing data from multiple studies will be able to reach power
values that are adequate to provide definitive answers on the issue.
Materials and Methods
Ethics Statement
All experimental procedures and written informed consent,
obtained from all donors, were reviewed and approved by the
Ethics Committee of the National Institute on Health and Science
on Aging (INRCA), Ancona, Italy, in accordance with the Euro-
pean Union Directive 86/609.
Samples
A sample of 904 unrelated subjects (433 males and 471 females)
age 40 years and older was collected by the Diabetology Unit,
INRCA (National Institute on Health and Science on Aging) in
Ancona (Italy). This included 466 patients affected with T2DM –
whose diagnosis was made according to the American Diabetes
Association Criteria (http://www.diabetes.org/) – and 438 control
cases. The mean age for each group was 65.8468.19 and
59.9669.97, respectively. To avoid population stratification
effects, only patients and controls with at least two generations
of maternal ancestry from the Marche region (Central Italy) were
included in this study. All five provinces of the region are
represented: 794 from Ancona; 42 from Macerata; 15 from Ascoli
Piceno; 3 from Pesaro and Urbino; 1 from Fermo; 49 of un-
specified Marchigian descent.
The basic phenotypical and clinical characteristics (including
data on vital signs, anthropometric factors, medical history, be-
havior and lifestyle, etc.) of the sample are summarized in Table 1.
A predominantly Mediterranean diet was reported by all subjects.
Controls did not show signs of illness and did not take any
prescription drugs. The presence/absence of microvascular and
macrovascular diabetic complications was evidenced as follows:
microvascular: (1) diabetic retinopathy by fundoscopy through
dilated pupils and/or fluorescence angiography, (2) incipient
nephropathy, defined by an excessive urinary albumin excretion
(.30 mg/24 h) and a normal creatinine clearance, (3) renal
failure, detected as an estimated glomerular filtration rate .60
mL/min per 1.73 m
2, and (4) neuropathy established by elec-
tromyography; macrovascular: (1) ischemic heart disease diag-
nosed by clinical history, and/or ischemic electrocardiographic
alterations, and (2) peripheral artery occlusive diseases (PAOD)
including atherosclerosis obliterans and cerebrovascular disease,
established on the basis of history, physical examinations and
Doppler velocimetry.
Hypertension was defined as a systolic blood pressure .140
mmHg and/or a diastolic blood pressure .90 mmHg. The values
were measured while the subjects were sitting and confirmed at
least three times. Overnight fasting venous blood samples from all
subjects were collected from 8:00 to 9:00 a.m. The biological
samples were either analyzed immediately or stored at 280uC for
no more than ten days. Blood concentrations for HDL cholesterol,
triglycerides, HbA1c, fasting insulin, fibrinogen, high-sensitivity C
reactive protein (hsCRP), creatinine, urea nitrogen, and white
blood cells count were measured by standard procedures.
MtDNA analysis
Total DNA was extracted from peripheral blood using standard
commercial kits (Qiamp DNA Blood Maxi Kit, Qiagen) and
stored at 220uC. The mtDNA from the 904 subjects was first
analyzed by sequencing ,800 bp from the control region for each
subject (at least from nucleotide position [np] 16024 to np 220),
thus including the entire hypervariable segment [HVS]-I [nps
16024–16383] and part of the HVS-II [nps 57–372]. The Gen-
Bank accession numbers for the 904 mtDNA control-region
sequences are JF716451-JF717354. This analysis was followed by
a hierarchical survey of haplogroup and sub-haplogroup diagnos-
tic markers in the coding region, which allowed the classification of
mtDNAs into different haplogroups and sub-haplogroups [32].
Also some paragroups were evaluated, for example paragroups H*
and HV* (Tables 2–3). A paragroup is a term used to indicate
lineages within a haplogroup that are not defined by additional
marker mutations either because the marker mutation(s) are
absent, or as yet undiscovered, or simply because they were not
evaluated in the molecular screening. They are generally repre-
sented by an asterisk placed after the name of the haplogroup. For
instance, our paragroup H* contains all (rather numerous) H
mtDNAs that did not cluster within any of the subclades of H
defined in the course of this study (H1, H3, H5, H6, H8 and H9).
Therefore, there is no specific marker(s) for H* in addition to
those that define the entire haplogroup H but, when statistically
evaluating H*, the potential role of the unknown markers within
H* can be assayed, eliminating the possible confounding effects of
H1, H3, H5, H6, H8 and H9.
Sequencing of entire mtDNA genomes (belonging to hap-
logroups R0a and H3) and phylogenetic analysis were performed
as previously described [5].
Statistics
Statistical analyses were performed using the SPSS statistical
package. Quantitative clinical data were compared between patients
with diabetes and control individuals by the unpaired Student’s t
test. Qualitative data were compared using the Fisher’s exact test.
Because multiple comparisons were made, the established statistical
significance (a#0.050) was Bonferroni corrected to a#0.004.
Binary logistic regressions were used to determine, simulta-
neously across the whole sample, whether the susceptibility to
develop T2DM or T2DM complications – represented by binary
dependent variables (or outcomes) taking on values 0 and 1) –
differed among haplogroups. This approach reduces the chance of
type I error (false-positive result) and controls for differences in the
frequency of key variables among the different groups. MtDNA
haplogroups are phylogenetically related, but they are also defined
by different clusters of haplotype-specific polymorphisms. Thus,
the categorical variable "haplogroup" is converted into different
dummy variables (or predictors, one for each haplogroup) and
introduced separately into the regression equation. To avoid small
sample sizes, some of the haplogroups were grouped following
phylogenetic considerations, whenever possible. The threshold was
established at .10 subjects across the whole patients’ group, in
keeping with the ‘‘rule of thumb’’ whereby logistic regression
should be performed only when the number of studied subjects is
one order of magnitude greater than each parameter. Thus, the
uncommon haplogroups H8 and H9 went into H (together with
H*); HV0 was grouped with the sister paragroup HV*; U4 and U9
were clustered together; U8b, K1 and K2 were considered as
U8b/K; R0a, W, the remaining U subclades (namely U1, U2, U6
and U7), and the African/Asian haplogroups were not included in
the logistic computation. After this correction, 16 (haplogroup)
classes were obtained. To find out how these combined predictors
affect the outcome variable (T2DM or T2DM complications) we
used a stepwise forward method with the likelihood ratio (LR) test
employed for entering the terms (probability thresholds: entry
0.05, since we have modeled two outcomes i.e. T2DM and T2DM
complications; removal 0.100): the initial model contained only the
constant (ß0); then the program searched for the predictor which
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significantly improved the model, it was retained; then the
program searched for the predictor which has the second highest
semi-partial correlation with the outcome; if this significantly
improved the model, it was retained, and so on. The chi-squared
significance of the obtained model was computed by calculating
the difference between log-likelihood statistic (-2LL) of the final
block and that of the first step. Since we have modeled 16
haplogroups only the model p-values less than 0.003 were con-
sidered statistically significant.
In order to verify the relationship between mitochondrial
haplogroups and T2DM complications we applied a decision tree
analysis. In particular, the significant groupings in the logistic
analyses (i.e. H3, H, U3 and V) were tested as predictors by Chi-
squared Automatic Interaction Detection (CHAID) [41]. The
CHAID tree was built by splitting subsets of the space into two or
more child nodes repeatedly. To determine the best split at any
node the CHAID algorithm merges each pair of categories of the
predictor variable until a non-significant pair is found with regard
to target variables. The process is repeated recursively until one of
the stopping rules is triggered. The CHAID algorithm incorpo-
rates a sequential merge and split procedure based on Chi-square
test statistics. In growing the tree the convergence criteria for
CHAID were: epsilon=0.001 and 100 maximum iterations. For
each node chi square tests are computed.
Power values for each haplogroup were calculated by following
the procedure previously described by Samuels et al. [40].
Supporting Information
Figure S1 CHAID diagrams assessing the association
between T2DM complications and candidate hap-
logroups. Chi-squared Automatic Interaction Detector (CHAID)
was used to develop decision-tree analyses for the evaluation of
T2DM complications, using those haplogroups that were significant
in logistic analyses (H3, H, U3 and V) as predictors. As shown on
panels ‘‘a-c’’, only H3 haplogroup entered in the decision tree when
predicting the presence of one or more complications and specifically
neuropathy. Panel ‘‘d’’ confirms that H haplogroup was the predictor
of retinopathy, while panels ‘‘e–f’’ confirm U3 and V as predictors of
nephropathy and renal failure, respectively.
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Table S1 Control-region haplotypes and haplogroup/
sub-haplogroup classification of the 904 mtDNAs from
the Marche region.
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haplogroups in diabetic patients also affected by
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